JP2015527399A5 - - Google Patents

Download PDF

Info

Publication number
JP2015527399A5
JP2015527399A5 JP2015531237A JP2015531237A JP2015527399A5 JP 2015527399 A5 JP2015527399 A5 JP 2015527399A5 JP 2015531237 A JP2015531237 A JP 2015531237A JP 2015531237 A JP2015531237 A JP 2015531237A JP 2015527399 A5 JP2015527399 A5 JP 2015527399A5
Authority
JP
Japan
Prior art keywords
fluoropyrazolo
indol
indole
dihydropyrazolo
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2015531237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015527399A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/058527 external-priority patent/WO2014039831A1/en
Publication of JP2015527399A publication Critical patent/JP2015527399A/ja
Publication of JP2015527399A5 publication Critical patent/JP2015527399A5/ja
Abandoned legal-status Critical Current

Links

JP2015531237A 2012-09-07 2013-09-06 置換−1,4−ジヒドロピラゾロ[4,3−b]インドール Abandoned JP2015527399A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261698369P 2012-09-07 2012-09-07
US61/698,369 2012-09-07
PCT/US2013/058527 WO2014039831A1 (en) 2012-09-07 2013-09-06 SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES

Publications (2)

Publication Number Publication Date
JP2015527399A JP2015527399A (ja) 2015-09-17
JP2015527399A5 true JP2015527399A5 (pt-PT) 2016-11-04

Family

ID=49170939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015531237A Abandoned JP2015527399A (ja) 2012-09-07 2013-09-06 置換−1,4−ジヒドロピラゾロ[4,3−b]インドール

Country Status (4)

Country Link
US (1) US9475816B2 (pt-PT)
EP (1) EP2909212B1 (pt-PT)
JP (1) JP2015527399A (pt-PT)
WO (1) WO2014039831A1 (pt-PT)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
HUE037371T2 (hu) 2012-12-07 2018-08-28 Vertex Pharma 2-Amino-6-fluor-N-(5-fluor-4-(4-(4-(oxetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il) pirazolo[1,5alfa]pirimidin-3-karboxamid mint ATR kináz inhibitor
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
AU2014360380B2 (en) 2013-12-06 2019-03-21 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
SG11201610197XA (en) 2014-06-05 2017-01-27 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
PL3157566T3 (pl) 2014-06-17 2019-10-31 Vertex Pharma Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017059357A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP2022543460A (ja) * 2019-08-06 2022-10-12 ドメイン・セラピューティクス 神経ペプチドff受容体アンタゴニストとしての5-ヘテロアリール-ピリジン-2-アミン化合物
CN113372281A (zh) * 2020-03-09 2021-09-10 河北中科金辉药业有限公司 一种特硝唑的合成方法
AU2021268094A1 (en) * 2020-05-08 2022-10-27 Cancer Research Technology Ltd. Tricyclic heterocycles useful as TEAD binders
AU2021401996A1 (en) * 2020-12-14 2023-07-13 Kinoxis Therapeutics Pty Ltd Oxytocin receptor modulators

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5612356A (en) 1992-12-28 1997-03-18 Eisai Co., Ltd. Heterocycle-containing carbonic acid derivatives
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6291505B1 (en) 1998-08-07 2001-09-18 Chiron Corporation Estrogen receptor modulators
IL142584A0 (en) * 1998-11-06 2002-03-10 Basf Ag Tricyclic pyrazole derivatives
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
AU2002215047A1 (en) 2000-11-21 2002-06-03 Smithkline Beecham Plc Isoquinoline derivatives useful in the treatment of cns disorders
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
BRPI0311179A2 (pt) 2002-05-15 2016-06-21 Janssen Pharmaceutica Nv 3-aminopirazóis tricíclicos n-substituídos como inibidores de receptor de pdfg
WO2004080973A1 (en) * 2003-03-07 2004-09-23 Abbott Laboratories Fused tri and tetra-cyclic pyrazole kinase inhibitors
JP5136929B2 (ja) 2004-03-24 2013-02-06 アボット・ラボラトリーズ 三環式ピラゾール系キナーゼ阻害薬
US7816536B2 (en) 2005-06-10 2010-10-19 The Research Foundation Of State University Of New York 4-substituted and 7-substituted indoles, benzofurans, benzothiophenes, benzimidazoles, benzoxazoles, and benzothiazoles and methods for making same
WO2008008650A1 (en) 2006-07-10 2008-01-17 Indiana University Research And Technology Corporation Methods for treating cystic kidney diseases
CN100586932C (zh) 2007-01-26 2010-02-03 中国医学科学院医药生物技术研究所 抗肿瘤化合物及其制备方法
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject

Similar Documents

Publication Publication Date Title
JP2015527399A5 (pt-PT)
US12084447B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
US11591336B2 (en) Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
AU2016287581B2 (en) Bicyclic lactams and methods of use thereof
CA2932425E (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
JP5775070B2 (ja) ヤヌスキナーゼ阻害剤としてのピラゾール−4−イル−ピロロ[2,3−d]ピリミジンおよびピロール−3−イル−ピロロ[2,3−d]ピリミジンのN−(ヘテロ)アリール−ピロリジン誘導体
JP2015537010A5 (pt-PT)
AU2010311378B2 (en) N-containing heteroaryl derivatives as JAK3 kinase inhibitors
JP2019535689A5 (pt-PT)
JP2017501202A5 (pt-PT)
JP2011526931A (ja) Cdkモジュレーター
JP2018530557A (ja) 置換ピラゾロ[3,4−b]ピリジン−6−カルボン酸およびこの使用
JP2021506941A5 (pt-PT)
JP2017518326A5 (pt-PT)
US20240190870A1 (en) Fgfr3 inhibitor compounds
CA2790847A1 (en) Fused bicyclic kinase inhibitors
US20240059703A1 (en) Heterocyclic spiro compounds and methods of use
JP2022535734A (ja) 縮合複素環誘導体
US20240109917A1 (en) Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
US20240174674A1 (en) Nitrogen-containing polycyclic fused ring compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
ZA200505935B (en) Pyrazolopyridine derivatives
WO2024076674A1 (en) Heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
WO2023247595A1 (en) Pyrazolopyrazine carboxamides and their uses as pdgfr inhibitors
WO2023247590A1 (en) Triazolopyridine and benzoisoxazole carboxamides and their uses as pdgfr inhibitors
US20230159558A1 (en) Spirotricycle ripk1 inhibitors and methods of uses thereof